Pacific Biosciences of California (PACB) Given Daily Media Impact Rating of 0.38

News stories about Pacific Biosciences of California (NASDAQ:PACB) have trended positive on Saturday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pacific Biosciences of California earned a news impact score of 0.38 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.3962583245601 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:

Pacific Biosciences of California (NASDAQ PACB) traded up $0.20 during trading hours on Friday, hitting $2.72. The company had a trading volume of 1,521,526 shares, compared to its average volume of 1,090,000. The company has a quick ratio of 3.15, a current ratio of 3.75 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $316.20, a P/E ratio of -2.99 and a beta of 1.75. Pacific Biosciences of California has a 12 month low of $2.51 and a 12 month high of $5.74.

Pacific Biosciences of California (NASDAQ:PACB) last posted its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01. The company had revenue of $23.54 million for the quarter, compared to the consensus estimate of $28.29 million. Pacific Biosciences of California had a negative return on equity of 97.50% and a negative net margin of 95.97%. The firm’s revenue for the quarter was down 6.3% on a year-over-year basis. During the same period in the previous year, the business earned ($0.19) earnings per share. equities research analysts predict that Pacific Biosciences of California will post -0.89 earnings per share for the current year.

A number of equities research analysts recently commented on PACB shares. BidaskClub downgraded Pacific Biosciences of California from a “sell” rating to a “strong sell” rating in a research report on Saturday. Zacks Investment Research downgraded Pacific Biosciences of California from a “hold” rating to a “sell” rating in a research report on Tuesday. CL King downgraded Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $6.80 target price on the stock. in a research report on Thursday, September 28th. Finally, First Analysis downgraded Pacific Biosciences of California from an “overweight” rating to an “equal weight” rating and set a $4.00 target price on the stock. in a research report on Friday, November 3rd. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $6.27.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at

About Pacific Biosciences of California

Pacific Biosciences of California, Inc designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes.

Insider Buying and Selling by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply